Public Act 100-0368
 
HB2534 EnrolledLRB100 08419 RLC 18533 b

    AN ACT concerning criminal law.
 
    Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
 
    Section 5. The Illinois Controlled Substances Act is
amended by changing Sections 204, 206, 208, 401, and 402 as
follows:
 
    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
    Sec. 204. (a) The controlled substances listed in this
Section are included in Schedule I.
    (b) Unless specifically excepted or unless listed in
another schedule, any of the following opiates, including their
isomers, esters, ethers, salts, and salts of isomers, esters,
and ethers, whenever the existence of such isomers, esters,
ethers and salts is possible within the specific chemical
designation:
        (1) Acetylmethadol;
        (1.1) Acetyl-alpha-methylfentanyl
    (N-[1-(1-methyl-2-phenethyl)-
    4-piperidinyl]-N-phenylacetamide);
        (2) Allylprodine;
        (3) Alphacetylmethadol, except
    levo-alphacetylmethadol (also known as levo-alpha-
    acetylmethadol, levomethadyl acetate, or LAAM);
        (4) Alphameprodine;
        (5) Alphamethadol;
        (6) Alpha-methylfentanyl
    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
    propanilido) piperidine;
        (6.1) Alpha-methylthiofentanyl
    (N-[1-methyl-2-(2-thienyl)ethyl-
    4-piperidinyl]-N-phenylpropanamide);
        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
        (7.1) PEPAP
    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
        (8) Benzethidine;
        (9) Betacetylmethadol;
        (9.1) Beta-hydroxyfentanyl
    (N-[1-(2-hydroxy-2-phenethyl)-
    4-piperidinyl]-N-phenylpropanamide);
        (10) Betameprodine;
        (11) Betamethadol;
        (12) Betaprodine;
        (13) Clonitazene;
        (14) Dextromoramide;
        (15) Diampromide;
        (16) Diethylthiambutene;
        (17) Difenoxin;
        (18) Dimenoxadol;
        (19) Dimepheptanol;
        (20) Dimethylthiambutene;
        (21) Dioxaphetylbutyrate;
        (22) Dipipanone;
        (23) Ethylmethylthiambutene;
        (24) Etonitazene;
        (25) Etoxeridine;
        (26) Furethidine;
        (27) Hydroxpethidine;
        (28) Ketobemidone;
        (29) Levomoramide;
        (30) Levophenacylmorphan;
        (31) 3-Methylfentanyl
    (N-[3-methyl-1-(2-phenylethyl)-
    4-piperidyl]-N-phenylpropanamide);
        (31.1) 3-Methylthiofentanyl
    (N-[(3-methyl-1-(2-thienyl)ethyl-
    4-piperidinyl]-N-phenylpropanamide);
        (32) Morpheridine;
        (33) Noracymethadol;
        (34) Norlevorphanol;
        (35) Normethadone;
        (36) Norpipanone;
        (36.1) Para-fluorofentanyl
    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
    4-piperidinyl]propanamide);
        (37) Phenadoxone;
        (38) Phenampromide;
        (39) Phenomorphan;
        (40) Phenoperidine;
        (41) Piritramide;
        (42) Proheptazine;
        (43) Properidine;
        (44) Propiram;
        (45) Racemoramide;
        (45.1) Thiofentanyl
    (N-phenyl-N-[1-(2-thienyl)ethyl-
    4-piperidinyl]-propanamide);
        (46) Tilidine;
        (47) Trimeperidine;
        (48) Beta-hydroxy-3-methylfentanyl (other name:
    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
    N-phenylpropanamide); .
        (49) Furanyl fentanyl (FU-F);
        (50) Butyryl fentanyl;
        (51) Valeryl fentanyl;
        (52) Acetyl fentanyl;
        (53) Beta-hydroxy-thiofentanyl;
        (54) 3,4-dichloro-N-[2-
    (dimethylamino)cyclohexyl]-N-
    methylbenzamide (U-47700); 
        (55) 4-chloro-N-[1-[2-
    (4-nitrophenyl)ethyl]-2-piperidinylidene]-
    benzenesulfonamide (W-18); 
        (56) 4-chloro-N-[1-(2-phenylethyl)
    -2-piperidinylidene]-benzenesulfonamide (W-15); 
        (57) acrylfentanyl (acryloylfentanyl). 
    (c) Unless specifically excepted or unless listed in
another schedule, any of the following opium derivatives, its
salts, isomers and salts of isomers, whenever the existence of
such salts, isomers and salts of isomers is possible within the
specific chemical designation:
        (1) Acetorphine;
        (2) Acetyldihydrocodeine;
        (3) Benzylmorphine;
        (4) Codeine methylbromide;
        (5) Codeine-N-Oxide;
        (6) Cyprenorphine;
        (7) Desomorphine;
        (8) Diacetyldihydromorphine (Dihydroheroin);
        (9) Dihydromorphine;
        (10) Drotebanol;
        (11) Etorphine (except hydrochloride salt);
        (12) Heroin;
        (13) Hydromorphinol;
        (14) Methyldesorphine;
        (15) Methyldihydromorphine;
        (16) Morphine methylbromide;
        (17) Morphine methylsulfonate;
        (18) Morphine-N-Oxide;
        (19) Myrophine;
        (20) Nicocodeine;
        (21) Nicomorphine;
        (22) Normorphine;
        (23) Pholcodine;
        (24) Thebacon.
    (d) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
hallucinogenic substances, or which contains any of its salts,
isomers and salts of isomers, whenever the existence of such
salts, isomers, and salts of isomers is possible within the
specific chemical designation (for the purposes of this
paragraph only, the term "isomer" includes the optical,
position and geometric isomers):
        (1) 3,4-methylenedioxyamphetamine
    (alpha-methyl,3,4-methylenedioxyphenethylamine,
    methylenedioxyamphetamine, MDA);
        (1.1) Alpha-ethyltryptamine
    (some trade or other names: etryptamine;
    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
    3-(2-aminobutyl)indole; a-ET; and AET);
        (2) 3,4-methylenedioxymethamphetamine (MDMA);
        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
    (also known as: N-ethyl-alpha-methyl-
    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
    and MDEA);
        (2.2) N-Benzylpiperazine (BZP);
        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
        (4) 3,4,5-trimethoxyamphetamine (TMA);
        (5) (Blank);
        (6) Diethyltryptamine (DET);
        (7) Dimethyltryptamine (DMT);
        (7.1) 5-Methoxy-diallyltryptamine;
        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
        (9) Ibogaine  (some trade and other names:
    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
    indole; Tabernanthe iboga);
        (10) Lysergic acid diethylamide;
        (10.1) Salvinorin A;
        (10.5) Salvia divinorum (meaning all parts of the plant
    presently classified botanically as Salvia divinorum,
    whether growing or not, the seeds thereof, any extract from
    any part of that plant, and every compound, manufacture,
    salts, isomers, and salts of isomers whenever the existence
    of such salts, isomers, and salts of isomers is possible
    within the specific chemical designation, derivative,
    mixture, or preparation of that plant, its seeds or
    extracts);
        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
        (12) Peyote (meaning all parts of the plant presently
    classified botanically as Lophophora williamsii Lemaire,
    whether growing or not, the seeds thereof, any extract from
    any part of that plant, and every compound, manufacture,
    salts, derivative, mixture, or preparation of that plant,
    its seeds or extracts);
        (13) N-ethyl-3-piperidyl benzilate (JB 318);
        (14) N-methyl-3-piperidyl benzilate;
        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
    (also known as N-hydroxy-alpha-methyl-
    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
        (15) Parahexyl; some trade or other names:
    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
    dibenzo (b,d) pyran; Synhexyl;
        (16) Psilocybin;
        (17) Psilocyn;
        (18) Alpha-methyltryptamine (AMT);
        (19) 2,5-dimethoxyamphetamine
    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
        (20) 4-bromo-2,5-dimethoxyamphetamine
    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
    4-bromo-2,5-DMA);
        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
    Some trade or other names: 2-(4-bromo-
    2,5-dimethoxyphenyl)-1-aminoethane;
    alpha-desmethyl DOB, 2CB, Nexus;
        (21) 4-methoxyamphetamine
    (4-methoxy-alpha-methylphenethylamine;
    paramethoxyamphetamine; PMA);
        (22) (Blank);
        (23) Ethylamine analog of phencyclidine.
    Some trade or other names:
    N-ethyl-1-phenylcyclohexylamine,
    (1-phenylcyclohexyl) ethylamine,
    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
        (24) Pyrrolidine analog of phencyclidine. Some trade
    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
    PHP;
        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
        (26) 2,5-dimethoxy-4-ethylamphetamine
    (another name: DOET);
        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
    (another name: TCPy);
        (28) (Blank);
        (29) Thiophene analog of phencyclidine (some trade
    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
    2-thienyl analog of phencyclidine; TPCP; TCP);
        (29.1) Benzothiophene analog of phencyclidine Some
    trade or other names: BTCP or benocyclidine;
        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
        (30) Bufotenine (some trade or other names:
    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
    3-(2-dimethylaminoethyl)-5-indolol;
    5-hydroxy-N,N-dimethyltryptamine;
    N,N-dimethylserotonin; mappine);
        (31) (Blank); 1-Pentyl-3-(1-naphthoyl)indole 
    Some trade or other names: JWH-018; 
        (32) (Blank); 1-Butyl-3-(1-naphthoyl)indole 
    Some trade or other names: JWH-073;  
        (33) (Blank); 1-[(5-fluoropentyl)-1H-indol-3-yl]- 
    (2-iodophenyl)methanone 
    Some trade or other names: AM-694;
        (34) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
    (2-methyloctan-2-yl)phenol 
    Some trade or other names: CP 47,497 
    and its C6, C8 and C9 homologs;
        (34.5) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5- 
    (2-methyloctan-2-yl)phenol), where side chain n=5;  
    and homologues where side chain n=4, 6, or 7; Some  
    trade or other names: CP 47,497; 
        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
    (2-methyloctan-2-yl)-6a,7, 
    10,10a-tetrahydrobenzo[c]chromen-1-ol
    Some trade or other names: HU-210; 
        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
    salts, and salts of isomers; Some trade or other  
    names: HU-210, Dexanabinol; 
        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
    Some trade or other names: HU-211;
        (37) (Blank); (2-methyl-1-propyl-1H-indol-
    3-yl)-1-naphthalenyl-methanone 
    Some trade or other names: JWH-015;
        (38) (Blank); 4-methoxynaphthalen-1-yl-
    (1-pentylindol-3-yl)methanone 
    Some trade or other names: JWH-081;
        (39) (Blank); 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
    Some trade or other names: JWH-122;
        (40) (Blank); 2-(2-methylphenyl)-1-(1-pentyl-
    1H-indol-3-yl)-ethanone 
    Some trade or other names: JWH-251;
        (41) (Blank); 1-(2-cyclohexylethyl)-3- 
    (2-methoxyphenylacetyl)indole 
    Some trade or other names: RCS-8, BTW-8 and SR-18; 
        (42)  Any compound structurally derived from 
    3-(1-naphthoyl)indole or 1H-indol-3-yl- 
    (1-naphthyl)methane by substitution at the 
    nitrogen atom of the indole ring by alkyl, haloalkyl, 
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 
    or 2-(4-morpholinyl)ethyl whether or not further 
    substituted in the indole ring to any extent, whether 
    or not substituted in the naphthyl ring to any extent.
    Examples of this structural class include, but are
    not limited to, JWH-018, AM-2201, JWH-175, JWH-184,
    and JWH-185;
        (43)  Any compound structurally derived from 
    3-(1-naphthoyl)pyrrole by substitution at the nitrogen 
    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, 
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
    aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
    or 2-(4-morpholinyl)ethyl, whether or not further 
    substituted in the pyrrole ring to any extent, whether 
    or not substituted in the naphthyl ring to any extent.
    Examples of this structural class include, but are not
    limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
    JWH-368; 
        (44)  Any compound structurally derived from 
    1-(1-naphthylmethyl)indene by substitution 
    at the 3-position of the indene ring by alkyl, haloalkyl, 
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
    halide, alkyl aryl halide, 1-(N-methyl-
    2-piperidinyl)methyl, or 2-(4-
    morpholinyl)ethyl whether or not further substituted in
    the indene ring to any extent, whether or not substituted
    in the naphthyl ring to any extent. Examples of
    this structural class include, but are not
    limited to, JWH-176; 
        (45)  Any compound structurally derived from 
    3-phenylacetylindole by substitution at the 
    nitrogen atom of the indole ring with alkyl, haloalkyl, 
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
    halide, alkyl aryl halide, 1-(N-methyl-2-
    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
    whether or not further substituted in the indole ring
    to any extent, whether or not substituted in the phenyl
    ring to any extent. Examples of this structural
    class include, but are not limited to, JWH-167,
    JWH-250, JWH-251, and RCS-8; 
        (46) Any compound structurally derived from 
    2-(3-hydroxycyclohexyl)phenol by substitution 
    at the 5-position of the phenolic ring by alkyl, 
    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
    whether or not substituted in the cyclohexyl ring to any
    extent. Examples of this structural class
    include, but are not limited to, CP 47,
    497 and its C8 homologue (cannabicyclohexanol); 
        (46.1) Any compound structurally 
    derived from Benzoylindoles: Any compound 
    containing a 3-(benzoyl) indole structure with 
    substitution at the nitrogen atom of the 
    indole ring by an alkyl, haloalkyl, alkenyl, 
    cycloalkylmethyl, cycloalkylethyl, 
    aryl halide, alkyl aryl halide, 
    1-(N-methyl-2-piperidinyl)methyl, 
    or 2-(4-morpholinyl)ethyl group 
    whether or not further substituted 
    in the indole ring to any extent and 
    whether or not substituted in the phenyl ring 
    to any extent. Examples of this structural class 
    include, but are not limited, to, AM-630, 
    AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; 
        (47) (Blank); 3,4-Methylenedioxymethcathinone 
    Some trade or other names: Methylone; 
        (48) (Blank); 3,4-Methyenedioxypyrovalerone 
    Some trade or other names: MDPV; 
        (49) (Blank); 4-Methylmethcathinone 
    Some trade or other names: Mephedrone; 
        (50) (Blank); 4-methoxymethcathinone; 
        (51) (Blank); 4-Fluoromethcathinone; 
        (52) (Blank); 3-Fluoromethcathinone; 
        (53)  2,5-Dimethoxy-4-(n)-propylthio- 
    phenethylamine; 
    Some trade or other names: 2C-T-7; 
        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine 
    Some trade or other names: 2C-E; 
        (53.2) 2,5-dimethoxy-4-methylphenethylamine 
    Some trade or other names: 2C-D; 
        (53.3) 4-chloro-2,5-dimethoxyphenethylamine 
    Some trade or other names: 2C-C; 
        (53.4) 4-iodo-2,5-dimethoxyphenethylamine 
    Some trade or other names: 2C-I; 
        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine 
    Some trade or other names: 2C-T-2; 
        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine 
    Some trade or other names: 2C-T-4; 
        (53.7) 2,5-dimethoxyphenethylamine 
    Some trade or other names: 2C-H; 
        (53.8) 2,5-dimethoxy-4-nitrophenethylamine 
    Some trade or other names: 2C-N; 
        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine 
    Some trade or other names: 2C-P; 
        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine 
    Some trade or other names: 2C-G; 
        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
    phenethylamine referred to in subparagraphs (20.1), (53),
    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
    (53.8), (53.9), and (53.10) including, but not limited to,
    25I-NBOMe and 25C-NBOMe;
        (54)  5-Methoxy-N,N-diisopropyltryptamine; 
        (55) (Blank); Pentedrone;  
        (56) (Blank); 4-iodo-2,5-dimethoxy-N-((2-methoxy 
    phenyl)methyl)-benzeneethanamine 
    (trade or other name: 25I-NBOMe); 
        (57) (Blank); 4-chloro-2,5-dimethoxy- 
    N-[(2-methoxyphenyl) methyl]-benzeneethanamine
    (trade or other name: 25C-NBOMe); 
        (58) (Blank); 4-bromo-2,5-dimethoxy 
    -N-[(2-methoxyphenyl) methyl]-benzeneethanamine
    (trade or other name: 25B-NBOMe); 
        (59)  3-cyclopropoylindole with 
    substitution at the nitrogen atom of the 
    indole ring by alkyl, haloalkyl, alkenyl, 
    cycloalkylmethyl, cycloalkylethyl, aryl 
    halide, alkyl aryl halide, 
    1-(N-methyl-2-piperidinyl)methyl, or 
    2-(4-morpholinyl)ethyl, whether or not 
    further substituted on the indole ring 
    to any extent, whether or not substituted 
    on the cyclopropyl ring to any extent: 
    including, but not limited to, XLR11, 
    UR144, FUB-144; 
        (60)  3-adamantoylindole with 
    substitution at the nitrogen atom of the 
    indole ring by alkyl, haloalkyl, alkenyl, 
    cycloalkylmethyl, cycloalkylethyl, 
    aryl halide, alkyl aryl halide, 
    1-(N-methyl-2-piperidinyl)methyl, or 
    2-(4-morpholinyl)ethyl, whether or not 
    further substituted on the indole ring to 
    any extent, whether or not substituted on 
    the adamantyl ring to any extent: including, 
    but not limited to, AB-001; 
        (61)  N-(adamantyl)-indole-3-carboxamide 
    with substitution at the nitrogen atom of the 
    indole ring by alkyl, haloalkyl, alkenyl, 
    cycloalkylmethyl, cycloalkylethyl, aryl halide, 
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 
    or 2-(4-morpholinyl)ethyl, whether or not further 
    substituted on the indole ring to any extent, whether 
    or not substituted on the adamantyl ring to any 
    extent: including, but not limited to, 
    APICA/2NE-1, STS-135; 
        (62)  N-(adamantyl)-indazole-3-carboxamide 
    with substitution at a nitrogen atom of the indazole 
    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
    cycloalkylethyl, aryl halide, alkyl aryl halide, 
    1-(N-methyl-2-piperidinyl)methyl, or 
    2-(4-morpholinyl)ethyl, whether or not further 
    substituted on the indazole ring to any extent, 
    whether or not substituted on the adamantyl 
    ring to any extent: including, but not limited 
    to, AKB48, 5F-AKB48; 
        (63)  1H-indole-3-carboxylic acid 8-quinolinyl 
    ester with substitution at the nitrogen atom of the 
    indole ring by alkyl, haloalkyl, alkenyl, 
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
    2-(4-morpholinyl)ethyl, whether or not further 
    substituted on the indole ring to any extent, 
    whether or not substituted on the quinoline ring 
    to any extent: including, but not limited to, PB22, 
    5F-PB22, FUB-PB-22; 
        (64)  3-(1-naphthoyl)indazole with 
    substitution at the nitrogen atom of the 
    indazole ring by alkyl, haloalkyl, 
    alkenyl, cycloalkylmethyl, cycloalkylethyl, 
    aryl halide, alkyl aryl halide, 
    1-(N-methyl-2-piperidinyl)methyl, or 
    2-(4-morpholinyl)ethyl, whether or not further 
    substituted on the indazole ring to any extent, 
    whether or not substituted on the naphthyl ring 
    to any extent: including, but not limited to, 
    THJ-018, THJ-2201; 
        (65)  2-(1-naphthoyl)benzimidazole with 
    substitution at the nitrogen atom of the benzimidazole 
    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
    cycloalkylethyl, aryl halide, alkyl aryl halide, 
    1-(N-methyl-2-piperidinyl)methyl, or 
    2-(4-morpholinyl)ethyl, whether or not further 
    substituted on the benzimidazole ring to any extent, 
    whether or not substituted on the naphthyl ring to 
    any extent: including, but not limited to, FUBIMINA; 
        (66)  N-(1-amino-3-methyl-1-oxobutan-2-yl) 
    -1H-indazole-3-carboxamide with substitution on the 
    nitrogen atom of the indazole ring by alkyl, 
    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
    whether or not further substituted on the indazole 
    ring to any extent: including, but not limited to, 
    AB-PINACA, AB-FUBINACA, AB-CHMINACA; 
        (67)  N-(1-amino-3,3-dimethyl-1-oxobutan- 
    2-yl)-1H-indazole-3-carboxamide with substitution 
    on the nitrogen atom of the indazole ring by alkyl, 
    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether 
    or not further substituted on the indazole ring to any 
    extent: including, but not limited to, ADB-PINACA, 
ADB-FUBINACA; 
        (68)  N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 
    1H-indole-3-carboxamide with substitution on the nitrogen 
    atom of the indole ring by alkyl, haloalkyl, alkenyl, 
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
    2-(4-morpholinyl)ethyl, whether or not further 
    substituted on the indole ring to any extent: 
    including, but not limited to, ADBICA, 5F-ADBICA; 
        (69)  N-(1-amino-3-methyl-1-oxobutan-2-yl)- 
    1H-indole-3-carboxamide with substitution on the 
    nitrogen atom of the indole ring by alkyl, haloalkyl, 
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
    halide, alkyl aryl halide, 1-(N-methyl-2- 
    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
    whether or not further substituted on the indole 
    ring to any extent: including, but not limited 
    to, ABICA, 5F-ABICA; 
        (70)  Methyl 2-(1H-indazole-3-carboxamido)- 
    3-methylbutanoate with substitution on the nitrogen 
    atom of the indazole ring by alkyl, haloalkyl, 
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
    halide, alkyl aryl halide, 1-(N-methyl-2- 
    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
    whether or not further substituted on the indazole 
    ring to any extent: including, but not limited to, AMB, 
5F-AMB. 
        (71) Methyl 2-(1H-indazole-3-carboxamido)
    -3,3-dimethylbutanoate with substitution on the nitrogen
    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-
    (4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; 
        (72) Methyl 2-(1H-indole-3-carboxamido)-
    3-methylbutanoate with substitution on the nitrogen atom
    of the indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
    or 2-(4-morpholinyl)ethyl, whether or not further
    substituted on the indazole ring to any extent:
    including, but not limited to, MMB018, MMB2201,
    and AMB-CHMICA; 
        (73) Methyl 2-(1H-indole-3-
    carboxamido)-3,3-dimethylbutanoate with substitution
    on the nitrogen atom of the indole ring by alkyl,
    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
    aryl halide, alkyl aryl halide, 1-(N-methyl-2-
    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
    whether or not further substituted on the
    indazole ring to any extent: including, but
    not limited to, MDMB-CHMICA; 
        (74) N-(1-Amino-1-oxo-3-phenylpropan
    -2-yl) -1H-indazole-3-carboxamide with
    substitution on the nitrogen atom of the indazole
    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
    cycloalkylethyl, aryl halide, alkyl aryl halide,
    1-(N-methyl-2-piperidinyl)methyl, or 2-(4-
    morpholinyl)ethyl, whether or not further
    substituted on the indazole ring to any
    extent: including, but not limited to, APP-CHMINACA,
    5-fluoro-APP-PINACA; 
        (75) N-(1-Amino-1-oxo-3-phenylpropan
    -2-yl)-1H-indole-3-carboxamide with substitution on
    the nitrogen atom of the indole ring by alkyl,
    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
    aryl halide, alkyl aryl halide, 1-(N-methyl-2-
    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
    whether or not further substituted on the indazole
    ring to any extent: including, but not limited to,
    APP-PICA and 5-fluoro-APP-PICA; 
        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
    4-AcO-DMT;
        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: Trade
    name 5-MeO-MIPT;
        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
    (4-HO-MiPT); 
        (82) Fluorophenylpiperazine;
        (83) Methoxetamine;
        (84) 1-(Ethylamino)-2-phenylpropan-2-
    one (iso-ethcathinone). 
    (e) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a depressant effect on the central nervous
system, including its salts, isomers, and salts of isomers
whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
        (1) mecloqualone;
        (2) methaqualone; and
        (3) gamma hydroxybutyric acid.
    (f) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system, including its salts, isomers, and salts of isomers:
        (1) Fenethylline;
        (2) N-ethylamphetamine;
        (3) Aminorex (some other names:
    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
    4-5-dihydro-5-phenyl-2-oxazolamine) and its
    salts, optical isomers, and salts of optical isomers;
        (4) Methcathinone (some other names:
    2-methylamino-1-phenylpropan-1-one;
    Ephedrone; 2-(methylamino)-propiophenone;
    alpha-(methylamino)propiophenone; N-methylcathinone;
    methycathinone; Monomethylpropion; UR 1431) and its
    salts, optical isomers, and salts of optical isomers;
        (5) Cathinone (some trade or other names:
    2-aminopropiophenone; alpha-aminopropiophenone;
    2-amino-1-phenyl-propanone; norephedrone);
        (6) N,N-dimethylamphetamine (also known as:
    N,N-alpha-trimethyl-benzeneethanamine;
    N,N-alpha-trimethylphenethylamine);
        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
        (8) 3,4-Methylenedioxypyrovalerone (MDPV); .
        (9) Halogenated amphetamines and
    methamphetamines  any compound derived from either
    amphetamine or methamphetamine through the substitution
    of a halogen on the phenyl ring, including, but not
    limited to, 2-fluoroamphetamine, 3-
    fluoroamphetamine and 4-fluoroamphetamine; 
        (10) Aminopropylbenzofuran (APB):
    including 4-(2-Aminopropyl) benzofuran, 5-
    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
        (11) Aminopropyldihydrobenzofuran (APDB):
    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
        (12) Methylaminopropylbenzofuran
    (MAPB): including 4-(2-methylaminopropyl)
    benzofuran, 5-(2-methylaminopropyl)benzofuran,
    6-(2-methylaminopropyl)benzofuran
    and 7-(2-methylaminopropyl)benzofuran. 
    (g) Temporary listing of substances subject to emergency
scheduling. Any material, compound, mixture, or preparation
that contains any quantity of the following substances:
        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
    (benzylfentanyl), its optical isomers, isomers, salts,
    and salts of isomers;
        (2) N-[1(2-thienyl)
   methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
   its optical isomers, salts, and salts of isomers.
    (h) Synthetic cathinones. Unless specifically excepted,
any chemical compound which is not approved by the United
States Food and Drug Administration or, if approved, is not
dispensed or possessed in accordance with State or federal law,
not including bupropion, structurally derived from
2-aminopropan-1-one by substitution at the 1-position with
either phenyl, naphthyl, or thiophene ring systems, whether or
not the compound is further modified in one or more of the
following ways:
        (1) by substitution in the ring system to 
    any extent with alkyl, alkylenedioxy, alkoxy, 
    haloalkyl, hydroxyl, or halide substituents, whether 
    or not further substituted in the ring system 
    by one or more other univalent substituents. 
    Examples of this class include, but are not 
    limited to, 3,4-Methylenedioxycathinone 
    (bk-MDA); 
        (2) by substitution at the 3-position 
    with an acyclic alkyl substituent. Examples of 
    this class include, but are not limited to, 
    2-methylamino-1-phenylbutan-1-one 
    (buphedrone); or 
        (3) by substitution at the 2-amino nitrogen 
    atom with alkyl, dialkyl, benzyl, or methoxybenzyl 
    groups, or by inclusion of the 2-amino nitrogen atom 
    in a cyclic structure. Examples of this class include, 
    but are not limited to, Dimethylcathinone, Ethcathinone, 
    and a-Pyrrolidinopropiophenone (a-PPP). 
(Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised
10-25-16.)
 
    (720 ILCS 570/206)  (from Ch. 56 1/2, par. 1206)
    Sec. 206. (a) The controlled substances listed in this
Section are included in Schedule II.
    (b) Unless specifically excepted or unless listed in
another schedule, any of the following substances whether
produced directly or indirectly by extraction from substances
of vegetable origin, or independently by means of chemical
synthesis, or by combination of extraction and chemical
synthesis:
        (1) Opium and opiates, and any salt, compound,
    derivative or preparation of opium or opiate, excluding
    apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
    nalmefene, naloxone, and naltrexone, and their respective
    salts, but including the following:
            (i) Raw Opium;
            (ii) Opium extracts;
            (iii) Opium fluid extracts;
            (iv) Powdered opium;
            (v) Granulated opium;
            (vi) Tincture of opium;
            (vii) Codeine;
            (viii) Ethylmorphine;
            (ix) Etorphine Hydrochloride;
            (x) Hydrocodone;
            (xi) Hydromorphone;
            (xii) Metopon;
            (xiii) Morphine;
            (xiii.5) 6-Monoacetylmorphine;
            (xiv) Oxycodone;
            (xv) Oxymorphone;
            (xv.5) Tapentadol;
            (xvi) Thebaine;
            (xvii) Thebaine-derived butorphanol.
            (xviii) Methorphan Dextromethorphan, except drug
        products containing dextromethorphan that may be
        dispensed pursuant to a prescription order of a
        practitioner and are sold in compliance with the safety
        and labeling standards as set forth by the United
        States Food and Drug Administration, or drug products
        containing dextromethorphan that are sold in solid,
        tablet, liquid, capsule, powder, thin film, or gel form
        and which are formulated, packaged, and sold in dosages
        and concentrations for use as an over-the-counter drug
        product. For the purposes of this Section,
        "over-the-counter drug product" means a drug that is
        available to consumers without a prescription and sold
        in compliance with the safety and labeling standards as
        set forth by the United States Food and Drug
        Administration.
        (2) Any salt, compound, isomer, derivative or
    preparation thereof which is chemically equivalent or
    identical with any of the substances referred to in
    subparagraph (1), but not including the isoquinoline
    alkaloids of opium;
        (3) Opium poppy and poppy straw;
        (4) Coca leaves and any salt, compound, isomer, salt of
    an isomer, derivative, or preparation of coca leaves
    including cocaine or ecgonine, and any salt, compound,
    isomer, derivative, or preparation thereof which is
    chemically equivalent or identical with any of these
    substances, but not including decocainized coca leaves or
    extractions of coca leaves which do not contain cocaine or
    ecgonine (for the purpose of this paragraph, the term
    "isomer" includes optical, positional and geometric
    isomers);
        (5) Concentrate of poppy straw (the crude extract of
    poppy straw in either liquid, solid or powder form which
    contains the phenanthrine alkaloids of the opium poppy).
    (c) Unless specifically excepted or unless listed in
another schedule any of the following opiates, including their
isomers, esters, ethers, salts, and salts of isomers, whenever
the existence of these isomers, esters, ethers and salts is
possible within the specific chemical designation, dextrorphan
excepted:
        (1) Alfentanil;
        (1.1) Carfentanil;
        (1.2) Thiafentanyl;
        (2) Alphaprodine;
        (3) Anileridine;
        (4) Bezitramide;
        (5) Bulk Dextropropoxyphene (non-dosage forms);
        (6) Dihydrocodeine;
        (7) Diphenoxylate;
        (8) Fentanyl;
        (9) Sufentanil;
        (9.5) Remifentanil;
        (10) Isomethadone;
        (11) (Blank); Levomethorphan;
        (12) Levorphanol (Levorphan);
        (13) Metazocine;
        (14) Methadone;
        (15) Methadone-Intermediate,
    4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
        (16) Moramide-Intermediate,
    2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
    acid;
        (17) Pethidine (meperidine);
        (18) Pethidine-Intermediate-A,
    4-cyano-1-methyl-4-phenylpiperidine;
        (19) Pethidine-Intermediate-B,
    ethyl-4-phenylpiperidine-4-carboxylate;
        (20) Pethidine-Intermediate-C,
    1-methyl-4-phenylpiperidine-4-carboxylic acid;
        (21) Phenazocine;
        (22) Piminodine;
        (23) Racemethorphan;
        (24) (Blank); Racemorphan;
        (25) Levo-alphacetylmethadol (some other names:
    levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
    (d) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system:
        (1) Amphetamine, its salts, optical isomers, and salts
    of its optical isomers;
        (2) Methamphetamine, its salts, isomers, and salts of
    its isomers;
        (3) Phenmetrazine and its salts;
        (4) Methylphenidate;
        (5) Lisdexamfetamine.
    (e) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a depressant effect on the central nervous
system, including its salts, isomers, and salts of isomers
whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
        (1) Amobarbital;
        (2) Secobarbital;
        (3) Pentobarbital;
        (4) Pentazocine;
        (5) Phencyclidine;
        (6) Gluthethimide;
        (7) (Blank).
    (f) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances:
        (1) Immediate precursor to amphetamine and
    methamphetamine:
            (i) Phenylacetone
        Some trade or other names: phenyl-2-propanone;
        P2P; benzyl methyl ketone; methyl benzyl ketone.
        (2) Immediate precursors to phencyclidine:
            (i) 1-phenylcyclohexylamine;
            (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
        (3) Nabilone.
(Source: P.A. 97-334, eff. 1-1-12.)
 
    (720 ILCS 570/208)  (from Ch. 56 1/2, par. 1208)
    Sec. 208. (a) The controlled substances listed in this
Section are included in Schedule III.
    (b) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system, including its salts, isomers (whether optical
position, or geometric), and salts of such isomers whenever the
existence of such salts, isomers, and salts of isomers is
possible within the specific chemical designation;
        (1) Those compounds, mixtures, or preparations in
    dosage unit form containing any stimulant substances
    listed in Schedule II which compounds, mixtures, or
    preparations were listed on August 25, 1971, as excepted
    compounds under Title 21, Code of Federal Regulations,
    Section 308.32, and any other drug of the quantitative
    composition shown in that list for those drugs or which is
    the same except that it contains a lesser quantity of
    controlled substances;
        (2) Benzphetamine;
        (3) Chlorphentermine;
        (4) Clortermine;
        (5) Phendimetrazine.
    (c) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a potential for abuse associated with a
depressant effect on the central nervous system:
        (1) Any compound, mixture, or preparation containing
    amobarbital, secobarbital, pentobarbital or any salt
    thereof and one or more other active medicinal ingredients
    which are not listed in any schedule;
        (2) Any suppository dosage form containing
    amobarbital, secobarbital, pentobarbital or any salt of
    any of these drugs and approved by the Federal Food and
    Drug Administration for marketing only as a suppository;
        (3) Any substance which contains any quantity of a
    derivative of barbituric acid, or any salt thereof:
        (3.1) Aprobarbital;
        (3.2) Butabarbital (secbutabarbital);
        (3.3) Butalbital;
        (3.4) Butobarbital (butethal);
        (4) Chlorhexadol;
        (5) Methyprylon;
        (6) Sulfondiethylmethane;
        (7) Sulfonethylmethane;
        (8) Sulfonmethane;
        (9) Lysergic acid;
        (10) Lysergic acid amide;
        (10.1) Tiletamine or zolazepam or both, or any salt of
    either of them.
    Some trade or other names for a tiletamine-zolazepam
    combination product: Telazol.
    Some trade or other names for Tiletamine:
    2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
    Some trade or other names for zolazepam:
    4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
    [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
        (11) Any material, compound, mixture or preparation
    containing not more than 12.5 milligrams of pentazocine or
    any of its salts, per 325 milligrams of aspirin;
        (12) Any material, compound, mixture or preparation
    containing not more than 12.5 milligrams of pentazocine or
    any of its salts, per 325 milligrams of acetaminophen;
        (13) Any material, compound, mixture or preparation
    containing not more than 50 milligrams of pentazocine or
    any of its salts plus naloxone HCl USP 0.5 milligrams, per
    dosage unit;
        (14) Ketamine;
        (15) Thiopental.
    (d) Nalorphine.
    (d.5) Buprenorphine.
    (e) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation containing limited quantities of any of the
following narcotic drugs, or their salts calculated as the free
anhydrous base or alkaloid, as set forth below:
        (1) not more than 1.8 grams of codeine per 100
    milliliters or not more than 90 milligrams per dosage unit,
    with an equal or greater quantity of an isoquinoline
    alkaloid of opium;
        (2) not more than 1.8 grams of codeine per 100
    milliliters or not more than 90 milligrams per dosage unit,
    with one or more active non-narcotic ingredients in
    recognized therapeutic amounts;
        (3) (blank); not more than 300 milligrams of
    dihydrocodeinone per 100 milliliters or not more than 15
    milligrams per dosage unit, with a fourfold or greater
    quantity of an isoquinoline alkaloid of opium;
        (4) (blank); not more than 300 milligrams of
    dihydrocodeinone per 100 milliliters or not more than 15
    milligrams per dosage unit, with one or more active,
    non-narcotic ingredients in recognized therapeutic
    amounts;
        (5) not more than 1.8 grams of dihydrocodeine per 100
    milliliters or not more than 90 milligrams per dosage unit,
    with one or more active, non-narcotic ingredients in
    recognized therapeutic amounts;
        (6) not more than 300 milligrams of ethylmorphine per
    100 milliliters or not more than 15 milligrams per dosage
    unit, with one or more active, non-narcotic ingredients in
    recognized therapeutic amounts;
        (7) not more than 500 milligrams of opium per 100
    milliliters or per 100 grams, or not more than 25
    milligrams per dosage unit, with one or more active,
    non-narcotic ingredients in recognized therapeutic
    amounts;
        (8) not more than 50 milligrams of morphine per 100
    milliliters or per 100 grams with one or more active,
    non-narcotic ingredients in recognized therapeutic
    amounts.
    (f) Anabolic steroids, except the following anabolic
steroids that are exempt:
        (1) Androgyn L.A.;
        (2) Andro-Estro 90-4;
        (3) depANDROGYN;
        (4) DEPO-T.E.;
        (5) depTESTROGEN;
        (6) Duomone;
        (7) DURATESTRIN;
        (8) DUO-SPAN II;
        (9) Estratest;
        (10) Estratest H.S.;
        (11) PAN ESTRA TEST;
        (12) Premarin with Methyltestosterone;
        (13) TEST-ESTRO Cypionates;
        (14) Testosterone Cyp 50 Estradiol Cyp 2;
        (15) Testosterone Cypionate-Estradiol Cypionate
    injection; and
        (16) Testosterone Enanthate-Estradiol Valerate
    injection.
    (g) Hallucinogenic substances.
        (1) Dronabinol (synthetic) in sesame oil and
    encapsulated in a soft gelatin capsule in a U.S. Food and
    Drug Administration approved product. Some other names for
    dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
    6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
    (-)-delta-9-(trans)-tetrahydrocannabinol.
        (2) (Reserved).
    (h) The Department may except by rule any compound,
mixture, or preparation containing any stimulant or depressant
substance listed in subsection (b) from the application of all
or any part of this Act if the compound, mixture, or
preparation contains one or more active medicinal ingredients
not having a stimulant or depressant effect on the central
nervous system, and if the admixtures are included therein in
combinations, quantity, proportion, or concentration that
vitiate the potential for abuse of the substances which have a
stimulant or depressant effect on the central nervous system.
(Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10;
97-334, eff. 1-1-12.)
 
    (720 ILCS 570/401)  (from Ch. 56 1/2, par. 1401)
    Sec. 401. Manufacture or delivery, or possession with
intent to manufacture or deliver, a controlled substance, a
counterfeit substance, or controlled substance analog. Except
as authorized by this Act, it is unlawful for any person
knowingly to manufacture or deliver, or possess with intent to
manufacture or deliver, a controlled substance other than
methamphetamine and other than bath salts as defined in the
Bath Salts Prohibition Act sold or offered for sale in a retail
mercantile establishment as defined in Section 16-0.1 of the
Criminal Code of 2012, a counterfeit substance, or a controlled
substance analog. A violation of this Act with respect to each
of the controlled substances listed herein constitutes a single
and separate violation of this Act. For purposes of this
Section, "controlled substance analog" or "analog" means a
substance, other than a controlled substance, which is not
approved by the United States Food and Drug Administration or,
if approved, is not dispensed or possessed in accordance with
State or federal law, and that has a chemical structure
substantially similar to that of a controlled substance in
Schedule I or II, or that was specifically designed to produce
an effect substantially similar to that of a controlled
substance in Schedule I or II. Examples of chemical classes in
which controlled substance analogs are found include, but are
not limited to, the following: phenethylamines, N-substituted
piperidines, morphinans, ecgonines, quinazolinones,
substituted indoles, and arylcycloalkylamines. For purposes of
this Act, a controlled substance analog shall be treated in the
same manner as the controlled substance to which it is
substantially similar.
    (a) Any person who violates this Section with respect to
the following amounts of controlled or counterfeit substances
or controlled substance analogs, notwithstanding any of the
provisions of subsections (c), (d), (e), (f), (g) or (h) to the
contrary, is guilty of a Class X felony and shall be sentenced
to a term of imprisonment as provided in this subsection (a)
and fined as provided in subsection (b):
        (1) (A) not less than 6 years and not more than 30
        years with respect to 15 grams or more but less than
        100 grams of a substance containing heroin, or an
        analog thereof;
            (B) not less than 9 years and not more than 40
        years with respect to 100 grams or more but less than
        400 grams of a substance containing heroin, or an
        analog thereof;
            (C) not less than 12 years and not more than 50
        years with respect to 400 grams or more but less than
        900 grams of a substance containing heroin, or an
        analog thereof;
            (D) not less than 15 years and not more than 60
        years with respect to 900 grams or more of any
        substance containing heroin, or an analog thereof;
        (1.5) (A) not less than 6 years and not more than 30
        years with respect to 15 grams or more but less than
        100 grams of a substance containing fentanyl, or an
        analog thereof;
            (B) not less than 9 years and not more than 40
        years with respect to 100 grams or more but less than
        400 grams of a substance containing fentanyl, or an
        analog thereof;
            (C) not less than 12 years and not more than 50
        years with respect to 400 grams or more but less than
        900 grams of a substance containing fentanyl, or an
        analog thereof;
            (D) not less than 15 years and not more than 60
        years with respect to 900 grams or more of a substance
        containing fentanyl, or an analog thereof;
        (2) (A) not less than 6 years and not more than 30
        years with respect to 15 grams or more but less than
        100 grams of a substance containing cocaine, or an
        analog thereof;
            (B) not less than 9 years and not more than 40
        years with respect to 100 grams or more but less than
        400 grams of a substance containing cocaine, or an
        analog thereof;
            (C) not less than 12 years and not more than 50
        years with respect to 400 grams or more but less than
        900 grams of a substance containing cocaine, or an
        analog thereof;
            (D) not less than 15 years and not more than 60
        years with respect to 900 grams or more of any
        substance containing cocaine, or an analog thereof;
        (3) (A) not less than 6 years and not more than 30
        years with respect to 15 grams or more but less than
        100 grams of a substance containing morphine, or an
        analog thereof;
            (B) not less than 9 years and not more than 40
        years with respect to 100 grams or more but less than
        400 grams of a substance containing morphine, or an
        analog thereof;
            (C) not less than 12 years and not more than 50
        years with respect to 400 grams or more but less than
        900 grams of a substance containing morphine, or an
        analog thereof;
            (D) not less than 15 years and not more than 60
        years with respect to 900 grams or more of a substance
        containing morphine, or an analog thereof;
        (4) 200 grams or more of any substance containing
    peyote, or an analog thereof;
        (5) 200 grams or more of any substance containing a
    derivative of barbituric acid or any of the salts of a
    derivative of barbituric acid, or an analog thereof;
        (6) 200 grams or more of any substance containing
    amphetamine or any salt of an optical isomer of
    amphetamine, or an analog thereof;
        (6.5) (blank);
        (6.6) (blank);
        (7) (A) not less than 6 years and not more than 30
        years with respect to: (i) 15 grams or more but less
        than 100 grams of a substance containing lysergic acid
        diethylamide (LSD), or an analog thereof, or (ii) 15 or
        more objects or 15 or more segregated parts of an
        object or objects but less than 200 objects or 200
        segregated parts of an object or objects containing in
        them or having upon them any amounts of any substance
        containing lysergic acid diethylamide (LSD), or an
        analog thereof;
            (B) not less than 9 years and not more than 40
        years with respect to: (i) 100 grams or more but less
        than 400 grams of a substance containing lysergic acid
        diethylamide (LSD), or an analog thereof, or (ii) 200
        or more objects or 200 or more segregated parts of an
        object or objects but less than 600 objects or less
        than 600 segregated parts of an object or objects
        containing in them or having upon them any amount of
        any substance containing lysergic acid diethylamide
        (LSD), or an analog thereof;
            (C) not less than 12 years and not more than 50
        years with respect to: (i) 400 grams or more but less
        than 900 grams of a substance containing lysergic acid
        diethylamide (LSD), or an analog thereof, or (ii) 600
        or more objects or 600 or more segregated parts of an
        object or objects but less than 1500 objects or 1500
        segregated parts of an object or objects containing in
        them or having upon them any amount of any substance
        containing lysergic acid diethylamide (LSD), or an
        analog thereof;
            (D) not less than 15 years and not more than 60
        years with respect to: (i) 900 grams or more of any
        substance containing lysergic acid diethylamide (LSD),
        or an analog thereof, or (ii) 1500 or more objects or
        1500 or more segregated parts of an object or objects
        containing in them or having upon them any amount of a
        substance containing lysergic acid diethylamide (LSD),
        or an analog thereof;
        (7.5) (A) not less than 6 years and not more than 30
        years with respect to: (i) 15 grams or more but less
        than 100 grams of a substance listed in paragraph (1),
        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
        (21), (25), or (26) of subsection (d) of Section 204,
        or an analog or derivative thereof, or (ii) 15 or more
        pills, tablets, caplets, capsules, or objects but less
        than 200 pills, tablets, caplets, capsules, or objects
        containing in them or having upon them any amounts of
        any substance listed in paragraph (1), (2), (2.1),
        (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
        (26) of subsection (d) of Section 204, or an analog or
        derivative thereof;
            (B) not less than 9 years and not more than 40
        years with respect to: (i) 100 grams or more but less
        than 400 grams of a substance listed in paragraph (1),
        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
        (21), (25), or (26) of subsection (d) of Section 204,
        or an analog or derivative thereof, or (ii) 200 or more
        pills, tablets, caplets, capsules, or objects but less
        than 600 pills, tablets, caplets, capsules, or objects
        containing in them or having upon them any amount of
        any substance listed in paragraph (1), (2), (2.1),
        (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
        (26) of subsection (d) of Section 204, or an analog or
        derivative thereof;
            (C) not less than 12 years and not more than 50
        years with respect to: (i) 400 grams or more but less
        than 900 grams of a substance listed in paragraph (1),
        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
        (21), (25), or (26) of subsection (d) of Section 204,
        or an analog or derivative thereof, or (ii) 600 or more
        pills, tablets, caplets, capsules, or objects but less
        than 1,500 pills, tablets, caplets, capsules, or
        objects containing in them or having upon them any
        amount of any substance listed in paragraph (1), (2),
        (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21),
        (25), or (26) of subsection (d) of Section 204, or an
        analog or derivative thereof;
            (D) not less than 15 years and not more than 60
        years with respect to: (i) 900 grams or more of any
        substance listed in paragraph (1), (2), (2.1), (2.2),
        (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
        subsection (d) of Section 204, or an analog or
        derivative thereof, or (ii) 1,500 or more pills,
        tablets, caplets, capsules, or objects containing in
        them or having upon them any amount of a substance
        listed in paragraph (1), (2), (2.1), (2.2), (3),
        (14.1), (19), (20), (20.1), (21), (25), or (26) of
        subsection (d) of Section 204, or an analog or
        derivative thereof;
        (8) 30 grams or more of any substance containing
    pentazocine or any of the salts, isomers and salts of
    isomers of pentazocine, or an analog thereof;
        (9) 30 grams or more of any substance containing
    methaqualone or any of the salts, isomers and salts of
    isomers of methaqualone, or an analog thereof;
        (10) 30 grams or more of any substance containing
    phencyclidine or any of the salts, isomers and salts of
    isomers of phencyclidine (PCP), or an analog thereof;
        (10.5) 30 grams or more of any substance containing
    ketamine or any of the salts, isomers and salts of isomers
    of ketamine, or an analog thereof;
        (10.6) 100 grams or more of any substance containing
    hydrocodone, or any of the salts, isomers and salts of
    isomers of hydrocodone, or an analog thereof;
        (10.7) (blank); 100 grams or more of any substance
    containing dihydrocodeinone, or any of the salts, isomers
    and salts of isomers of dihydrocodeinone, or an analog
    thereof;
        (10.8) 100 grams or more of any substance containing
    dihydrocodeine, or any of the salts, isomers and salts of
    isomers of dihydrocodeine, or an analog thereof;
        (10.9) 100 grams or more of any substance containing
    oxycodone, or any of the salts, isomers and salts of
    isomers of oxycodone, or an analog thereof;
        (11) 200 grams or more of any substance containing any
    other controlled substance classified in Schedules I or II,
    or an analog thereof, which is not otherwise included in
    this subsection.
    (b) Any person sentenced with respect to violations of
paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
involving 100 grams or more of the controlled substance named
therein, may in addition to the penalties provided therein, be
fined an amount not more than $500,000 or the full street value
of the controlled or counterfeit substance or controlled
substance analog, whichever is greater. The term "street value"
shall have the meaning ascribed in Section 110-5 of the Code of
Criminal Procedure of 1963. Any person sentenced with respect
to any other provision of subsection (a), may in addition to
the penalties provided therein, be fined an amount not to
exceed $500,000.
    (b-1) Excluding violations of this Act when the controlled
substance is fentanyl, any person sentenced to a term of
imprisonment with respect to violations of Section 401, 401.1,
405, 405.1, 405.2, or 407, when the substance containing the
controlled substance contains any amount of fentanyl, 3 years
shall be added to the term of imprisonment imposed by the
court, and the maximum sentence for the offense shall be
increased by 3 years.
    (c) Any person who violates this Section with regard to the
following amounts of controlled or counterfeit substances or
controlled substance analogs, notwithstanding any of the
provisions of subsections (a), (b), (d), (e), (f), (g) or (h)
to the contrary, is guilty of a Class 1 felony. The fine for
violation of this subsection (c) shall not be more than
$250,000:
        (1) 1 gram or more but less than 15 grams of any
    substance containing heroin, or an analog thereof;
        (1.5) 1 gram or more but less than 15 grams of any
    substance containing fentanyl, or an analog thereof;
        (2) 1 gram or more but less than 15 grams of any
    substance containing cocaine, or an analog thereof;
        (3) 10 grams or more but less than 15 grams of any
    substance containing morphine, or an analog thereof;
        (4) 50 grams or more but less than 200 grams of any
    substance containing peyote, or an analog thereof;
        (5) 50 grams or more but less than 200 grams of any
    substance containing a derivative of barbituric acid or any
    of the salts of a derivative of barbituric acid, or an
    analog thereof;
        (6) 50 grams or more but less than 200 grams of any
    substance containing amphetamine or any salt of an optical
    isomer of amphetamine, or an analog thereof;
        (6.5) (blank);
        (7) (i) 5 grams or more but less than 15 grams of any
    substance containing lysergic acid diethylamide (LSD), or
    an analog thereof, or (ii) more than 10 objects or more
    than 10 segregated parts of an object or objects but less
    than 15 objects or less than 15 segregated parts of an
    object containing in them or having upon them any amount of
    any substance containing lysergic acid diethylamide (LSD),
    or an analog thereof;
        (7.5) (i) 5 grams or more but less than 15 grams of any
    substance listed in paragraph (1), (2), (2.1), (2.2), (3),
    (14.1), (19), (20), (20.1), (21), (25), or (26) of
    subsection (d) of Section 204, or an analog or derivative
    thereof, or (ii) more than 10 pills, tablets, caplets,
    capsules, or objects but less than 15 pills, tablets,
    caplets, capsules, or objects containing in them or having
    upon them any amount of any substance listed in paragraph
    (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
    (21), (25), or (26) of subsection (d) of Section 204, or an
    analog or derivative thereof;
        (8) 10 grams or more but less than 30 grams of any
    substance containing pentazocine or any of the salts,
    isomers and salts of isomers of pentazocine, or an analog
    thereof;
        (9) 10 grams or more but less than 30 grams of any
    substance containing methaqualone or any of the salts,
    isomers and salts of isomers of methaqualone, or an analog
    thereof;
        (10) 10 grams or more but less than 30 grams of any
    substance containing phencyclidine or any of the salts,
    isomers and salts of isomers of phencyclidine (PCP), or an
    analog thereof;
        (10.5) 10 grams or more but less than 30 grams of any
    substance containing ketamine or any of the salts, isomers
    and salts of isomers of ketamine, or an analog thereof;
        (10.6) 50 grams or more but less than 100 grams of any
    substance containing hydrocodone, or any of the salts,
    isomers and salts of isomers of hydrocodone, or an analog
    thereof;
        (10.7) (blank); 50 grams or more but less than 100
    grams of any substance containing dihydrocodeinone, or any
    of the salts, isomers and salts of isomers of
    dihydrocodeinone, or an analog thereof;
        (10.8) 50 grams or more but less than 100 grams of any
    substance containing dihydrocodeine, or any of the salts,
    isomers and salts of isomers of dihydrocodeine, or an
    analog thereof;
        (10.9) 50 grams or more but less than 100 grams of any
    substance containing oxycodone, or any of the salts,
    isomers and salts of isomers of oxycodone, or an analog
    thereof;
        (11) 50 grams or more but less than 200 grams of any
    substance containing a substance classified in Schedules I
    or II, or an analog thereof, which is not otherwise
    included in this subsection.
    (c-5) (Blank).
    (d) Any person who violates this Section with regard to any
other amount of a controlled or counterfeit substance
containing dihydrocodeinone or dihydrocodeine or classified in
Schedules I or II, or an analog thereof, which is (i) a
narcotic drug, (ii) lysergic acid diethylamide (LSD) or an
analog thereof, (iii) any substance containing amphetamine or
fentanyl or any salt or optical isomer of amphetamine or
fentanyl, or an analog thereof, or (iv) any substance
containing N-Benzylpiperazine (BZP) or any salt or optical
isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
guilty of a Class 2 felony. The fine for violation of this
subsection (d) shall not be more than $200,000.
    (d-5) (Blank).
    (e) Any person who violates this Section with regard to any
other amount of a controlled substance other than
methamphetamine or counterfeit substance classified in
Schedule I or II, or an analog thereof, which substance is not
included under subsection (d) of this Section, is guilty of a
Class 3 felony. The fine for violation of this subsection (e)
shall not be more than $150,000.
    (f) Any person who violates this Section with regard to any
other amount of a controlled or counterfeit substance
classified in Schedule III is guilty of a Class 3 felony. The
fine for violation of this subsection (f) shall not be more
than $125,000.
    (g) Any person who violates this Section with regard to any
other amount of a controlled or counterfeit substance
classified in Schedule IV is guilty of a Class 3 felony. The
fine for violation of this subsection (g) shall not be more
than $100,000.
    (h) Any person who violates this Section with regard to any
other amount of a controlled or counterfeit substance
classified in Schedule V is guilty of a Class 3 felony. The
fine for violation of this subsection (h) shall not be more
than $75,000.
    (i) This Section does not apply to the manufacture,
possession or distribution of a substance in conformance with
the provisions of an approved new drug application or an
exemption for investigational use within the meaning of Section
505 of the Federal Food, Drug and Cosmetic Act.
    (j) (Blank).
(Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17.)
 
    (720 ILCS 570/402)  (from Ch. 56 1/2, par. 1402)
    Sec. 402. Except as otherwise authorized by this Act, it is
unlawful for any person knowingly to possess a controlled or
counterfeit substance or controlled substance analog. A
violation of this Act with respect to each of the controlled
substances listed herein constitutes a single and separate
violation of this Act. For purposes of this Section,
"controlled substance analog" or "analog" means a substance,
other than a controlled substance, which is not approved by the
United States Food and Drug Administration or, if approved, is
not dispensed or possessed in accordance with State or federal
law, and that has a chemical structure substantially similar to
that of a controlled substance in Schedule I or II, or that was
specifically designed to produce an effect substantially
similar to that of a controlled substance in Schedule I or II.
Examples of chemical classes in which controlled substance
analogs are found include, but are not limited to, the
following: phenethylamines, N-substituted piperidines,
morphinans, ecgonines, quinazolinones, substituted indoles,
and arylcycloalkylamines. For purposes of this Act, a
controlled substance analog shall be treated in the same manner
as the controlled substance to which it is substantially
similar.
    (a) Any person who violates this Section with respect to
the following controlled or counterfeit substances and
amounts, notwithstanding any of the provisions of subsections
(c) and (d) to the contrary, is guilty of a Class 1 felony and
shall, if sentenced to a term of imprisonment, be sentenced as
provided in this subsection (a) and fined as provided in
subsection (b):
        (1) (A) not less than 4 years and not more than 15
        years with respect to 15 grams or more but less than
        100 grams of a substance containing heroin;
            (B) not less than 6 years and not more than 30
        years with respect to 100 grams or more but less than
        400 grams of a substance containing heroin;
            (C) not less than 8 years and not more than 40
        years with respect to 400 grams or more but less than
        900 grams of any substance containing heroin;
            (D) not less than 10 years and not more than 50
        years with respect to 900 grams or more of any
        substance containing heroin;
        (2) (A) not less than 4 years and not more than 15
        years with respect to 15 grams or more but less than
        100 grams of any substance containing cocaine;
            (B) not less than 6 years and not more than 30
        years with respect to 100 grams or more but less than
        400 grams of any substance containing cocaine;
            (C) not less than 8 years and not more than 40
        years with respect to 400 grams or more but less than
        900 grams of any substance containing cocaine;
            (D) not less than 10 years and not more than 50
        years with respect to 900 grams or more of any
        substance containing cocaine;
        (3) (A) not less than 4 years and not more than 15
        years with respect to 15 grams or more but less than
        100 grams of any substance containing morphine;
            (B) not less than 6 years and not more than 30
        years with respect to 100 grams or more but less than
        400 grams of any substance containing morphine;
            (C) not less than 6 years and not more than 40
        years with respect to 400 grams or more but less than
        900 grams of any substance containing morphine;
            (D) not less than 10 years and not more than 50
        years with respect to 900 grams or more of any
        substance containing morphine;
        (4) 200 grams or more of any substance containing
    peyote;
        (5) 200 grams or more of any substance containing a
    derivative of barbituric acid or any of the salts of a
    derivative of barbituric acid;
        (6) 200 grams or more of any substance containing
    amphetamine or any salt of an optical isomer of
    amphetamine;
        (6.5) (blank);
        (7) (A) not less than 4 years and not more than 15
        years with respect to: (i) 15 grams or more but less
        than 100 grams of any substance containing lysergic
        acid diethylamide (LSD), or an analog thereof, or (ii)
        15 or more objects or 15 or more segregated parts of an
        object or objects but less than 200 objects or 200
        segregated parts of an object or objects containing in
        them or having upon them any amount of any substance
        containing lysergic acid diethylamide (LSD), or an
        analog thereof;
            (B) not less than 6 years and not more than 30
        years with respect to: (i) 100 grams or more but less
        than 400 grams of any substance containing lysergic
        acid diethylamide (LSD), or an analog thereof, or (ii)
        200 or more objects or 200 or more segregated parts of
        an object or objects but less than 600 objects or less
        than 600 segregated parts of an object or objects
        containing in them or having upon them any amount of
        any substance containing lysergic acid diethylamide
        (LSD), or an analog thereof;
            (C) not less than 8 years and not more than 40
        years with respect to: (i) 400 grams or more but less
        than 900 grams of any substance containing lysergic
        acid diethylamide (LSD), or an analog thereof, or (ii)
        600 or more objects or 600 or more segregated parts of
        an object or objects but less than 1500 objects or 1500
        segregated parts of an object or objects containing in
        them or having upon them any amount of any substance
        containing lysergic acid diethylamide (LSD), or an
        analog thereof;
            (D) not less than 10 years and not more than 50
        years with respect to: (i) 900 grams or more of any
        substance containing lysergic acid diethylamide (LSD),
        or an analog thereof, or (ii) 1500 or more objects or
        1500 or more segregated parts of an object or objects
        containing in them or having upon them any amount of a
        substance containing lysergic acid diethylamide (LSD),
        or an analog thereof;
        (7.5) (A) not less than 4 years and not more than 15
        years with respect to: (i) 15 grams or more but less
        than 100 grams of any substance listed in paragraph
        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
        (20.1), (21), (25), or (26) of subsection (d) of
        Section 204, or an analog or derivative thereof, or
        (ii) 15 or more pills, tablets, caplets, capsules, or
        objects but less than 200 pills, tablets, caplets,
        capsules, or objects containing in them or having upon
        them any amount of any substance listed in paragraph
        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
        (20.1), (21), (25), or (26) of subsection (d) of
        Section 204, or an analog or derivative thereof;
            (B) not less than 6 years and not more than 30
        years with respect to: (i) 100 grams or more but less
        than 400 grams of any substance listed in paragraph
        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
        (20.1), (21), (25), or (26) of subsection (d) of
        Section 204, or an analog or derivative thereof, or
        (ii) 200 or more pills, tablets, caplets, capsules, or
        objects but less than 600 pills, tablets, caplets,
        capsules, or objects containing in them or having upon
        them any amount of any substance listed in paragraph
        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
        (20.1), (21), (25), or (26) of subsection (d) of
        Section 204, or an analog or derivative thereof;
            (C) not less than 8 years and not more than 40
        years with respect to: (i) 400 grams or more but less
        than 900 grams of any substance listed in paragraph
        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
        (20.1), (21), (25), or (26) of subsection (d) of
        Section 204, or an analog or derivative thereof, or
        (ii) 600 or more pills, tablets, caplets, capsules, or
        objects but less than 1,500 pills, tablets, caplets,
        capsules, or objects containing in them or having upon
        them any amount of any substance listed in paragraph
        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
        (20.1), (21), (25), or (26) of subsection (d) of
        Section 204, or an analog or derivative thereof;
            (D) not less than 10 years and not more than 50
        years with respect to: (i) 900 grams or more of any
        substance listed in paragraph (1), (2), (2.1), (2.2),
        (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
        subsection (d) of Section 204, or an analog or
        derivative thereof, or (ii) 1,500 or more pills,
        tablets, caplets, capsules, or objects containing in
        them or having upon them any amount of a substance
        listed in paragraph (1), (2), (2.1), (2.2), (3),
        (14.1), (19), (20), (20.1), (21), (25), or (26) of
        subsection (d) of Section 204, or an analog or
        derivative thereof;
        (8) 30 grams or more of any substance containing
    pentazocine or any of the salts, isomers and salts of
    isomers of pentazocine, or an analog thereof;
        (9) 30 grams or more of any substance containing
    methaqualone or any of the salts, isomers and salts of
    isomers of methaqualone;
        (10) 30 grams or more of any substance containing
    phencyclidine or any of the salts, isomers and salts of
    isomers of phencyclidine (PCP);
        (10.5) 30 grams or more of any substance containing
    ketamine or any of the salts, isomers and salts of isomers
    of ketamine;
        (11) 200 grams or more of any substance containing any
    substance classified as a narcotic drug in Schedules I or
    II, or an analog thereof, which is not otherwise included
    in this subsection.
    (b) Any person sentenced with respect to violations of
paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
involving 100 grams or more of the controlled substance named
therein, may in addition to the penalties provided therein, be
fined an amount not to exceed $200,000 or the full street value
of the controlled or counterfeit substances, whichever is
greater. The term "street value" shall have the meaning
ascribed in Section 110-5 of the Code of Criminal Procedure of
1963. Any person sentenced with respect to any other provision
of subsection (a), may in addition to the penalties provided
therein, be fined an amount not to exceed $200,000.
    (c) Any person who violates this Section with regard to an
amount of a controlled substance other than methamphetamine or
counterfeit substance not set forth in subsection (a) or (d) is
guilty of a Class 4 felony. The fine for a violation punishable
under this subsection (c) shall not be more than $25,000.
    (d) Any person who violates this Section with regard to any
amount of anabolic steroid is guilty of a Class C misdemeanor
for the first offense and a Class B misdemeanor for a
subsequent offense committed within 2 years of a prior
conviction.
(Source: P.A. 99-371, eff. 1-1-16.)